Chen D. Gou to Become Chairman of

Braincure Biotech has recently appointed Chen D. Gou will become Chairman of the Company’s Board of Directors, effective immediately.


Taipei City, Taiwan -- (SBWIRE) -- 12/28/2015 -- Braincure Biotech (ISIN:TW0001327872) has recently appointed Chen D. Gou will become Chairman of the Company's Board of Directors, effective immediately. The appointment follows the decision by Tsao T. Wenjung, 65, the Company's former Chairman, to retire from his position. Mr. Wenjung will retire from the Board at the Company's Annual Shareholder Meeting.

The Board stated, "We are deeply appreciative of all that Tsao Wenjung has accomplished in his tenure as Chairman of Braincure Biotech's Board and his 13 years as Director. During his time, the Company developed and brought to market products that have made a real difference in the lives of many; this is the most important aspect for us and our company's mission."

Mr. Wenjung said, "It has been a fulfilling experience to serve with such a distinguished group of directors and have had the opportunity to serve the shareholders of such a great company. I am pleased the Board has selected Chen Gou as Braincure Biotech's new Chairman. He is an experienced biotechnology and pharmaceutical industry executive with an extensive understanding of Braincure Biotech in his service as a Director of the Company."

The Board also announced today that Lee Feng, a Director of the Company, is stepping down, effective at year end, before assuming his responsibilities as the new Chief Executive Officer of a top pharmaceutical company.

"We are grateful for Lee Feng's contributions as a Director of Braincure Biotech, and we wish him well as he assumes his new professional responsibilities," said Mr. Wenjung.

About Braincure Biotech is a state-of-the-art technology research company that uses discoveries in neuroimmunolgy and human genetics to develop novel therapeutics for Alzheimer's disease, other forms of dementia, and mechanistically similar disorders. Braincure Biotech's strategy is to efficiently generate and validate antibody drugs with unique functional properties that engage key disease-altering targets. The goal of the firm is to discover and develop novel, disease modifying therapies for dementia and mechanistically similar disorders. The highly professional and acclaimed team of scientists maintains an innovative and motivating environment in which every employee has the possibility to contribute to our joint success and to grow individually.

For Media Contact:
Address: Taipei Far Eastern Plaza
No. 207, Section 2
Dun Hua South Road,
Taipei 106, Taiwan